Understanding Immunotherapy
Immunotherapy encompasses treatments that stimulate or restore the immune system’s ability to fight cancer. Key strategies include:
Immune checkpoint inhibitors
Cancer vaccines
Adoptive cell therapies
These therapies aim to recognize and target cancer cells more effectively, reducing tumor growth and spread.
Immunotherapy in Breast Cancer
Breast cancer, one of the most common cancers among women, has seen significant advancements with immunotherapy. In triple-negative breast cancer (TNBC), which lacks estrogen, progesterone, and HER2 receptors, immunotherapy has shown promise. The immune checkpoint inhibitor pembrolizumab (Keytruda) has been studied in combination with chemotherapy for early-stage TNBC. Recent studies presented at the European Society for Medical Oncology (ESMO) reported:
87% of patients receiving this combination were alive after five years.
Compared to 82% survival with chemotherapy alone.
Immunotherapy in Ovarian Cancer
Ovarian cancer remains a leading cause of gynecologic cancer deaths. Researchers at the University of Oxford are developing OvarianVax, a vaccine designed to train the immune system to recognize and target early-stage ovarian cancer cells. If successful, it could be administered preventatively, similar to the HPV vaccine for cervical cancer.
Additionally, antibody-drug conjugates (ADCs) targeting specific proteins like claudin 6 have shown promising antitumor activity in heavily pre-treated ovarian and endometrial cancer patients.
Immunotherapy in Endometrial Cancer
Endometrial cancer, which affects the lining of the uterus, has also been a focus of immunotherapy research. Studies have indicated that patients with deficient mismatch repair (dMMR) tumors may benefit from immune checkpoint inhibitors.
A phase 3 randomized study found that adding pembrolizumab to chemotherapy after surgery did not improve disease-free survival in the overall population.
However, subgroup analysis revealed clinically meaningful improvements in patients with dMMR tumors.
Immunotherapy in Cervical Cancer
Cervical cancer, often linked to human papillomavirus (HPV) infection, has also seen advancements in treatment with immunotherapy. A phase 3 study reported:
Adding pembrolizumab to concurrent chemoradiotherapy significantly improved overall survival in patients with high-risk locally advanced cervical cancer.
The three-year overall survival rate was 82.6% in the pembrolizumab group compared to 74.8% in the placebo group.
These findings suggest a new standard of care for these patients.
Advancements and Future Directions
The landscape of immunotherapy in women’s cancers is rapidly evolving. Beyond checkpoint inhibitors, research is exploring cancer vaccines aimed at preventing cancers in high-risk individuals. For instance:
Vaccines targeting specific genetic mutations associated with increased cancer risk are under investigation.
Combining immunotherapy with other treatments such as chemotherapy, radiotherapy, and targeted agents is being studied to enhance efficacy.
Personalized medicine approaches, including neoantigen vaccines tailored to an individual’s tumor profile, represent a new frontier in cancer treatment.
These advancements aim to improve outcomes while minimizing side effects.
Conclusion
Immunotherapy has ushered in a new era in the treatment of women’s cancers, offering hope for improved survival and quality of life. Ongoing research continues to refine these therapies, striving to make them more effective and accessible. As our understanding of the immune system’s interaction with cancer deepens, immunotherapy is poised to play an increasingly central role in oncology, transforming the outlook for patients with breast, ovarian, endometrial, and cervical cancers.
Dr. Mohamed Zehran Saipillai
Consultant-Medical Oncology
